Desk›Healthcare› Aarti Drugs Ltd
Aarti Drugs Ltd
BSE 524348 · NSE AARTIDRUGS · ISIN INE767A01016 · Group B · Active
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
₹417.60
-0.10%
BSE close, 28 August 2026
₹3,811.44 cr
9.1 cr shares · Micro cap
₹1,488.04 cr
as published
22.2× · 3.29×
EPS ₹18.78 · BV ₹126.93
2,260.39 / 169.22
₹ cr, as filed
25
7 selected · 28%
Reg 30
Sch. III Part A
Price 52-week, BSE
| Against 52-week high | -21.8% |
|---|---|
| Against 52-week low | +31.1% |
| Day change | -0.10% |
| Size band | Micro cap |
| Index membership | None |
Valuation as published by BSE
| Earnings per share | ₹18.78 |
|---|---|
| Price / earnings | 22.24× |
| Price / book | 3.29× |
| Book value — derived, price ÷ P/B | ₹126.93 |
| Return on equity | 14.79% |
| Operating margin | 14.35% |
| Net margin | 8.10% |
Consistency check
- P/B ÷ P/E, which must equal ROE
- 14.79%
- ROE as published
- 14.79%
Results ₹ crore, as filed
RevenueNet profit one scale across all three periods, ₹ crore
| Period | Revenue ₹cr | Net profit ₹cr | EPS ₹ | OPM | NPM |
|---|---|---|---|---|---|
| Jun-26 · Q | 627.45 | 50.85 | 5.57 | 14.35% | 8.10% |
| Mar-26 · Q | 631.68 | 44.96 | 4.93 | 12.68% | 7.12% |
| FY25-26 | 2,260.39 | 169.22 | 18.54 | 11.65% | 7.49% |
Quarter on quarter
- Revenue, quarter on quarter
- -0.7%
- Net profit, quarter on quarter
- +13.1%
- Operating margin, quarter on quarter
- +167 bps
Disclosure profile 25 filings in the window
| Tag | Filings |
|---|---|
| Selected | |
| Board Outcome | 2 |
| Change in Directorate | 1 |
| Change in Management | 1 |
| Concall Transcript | 1 |
| Press Release | 1 |
| Results | 1 |
| Selected sub-total | 7 |
| Procedural | |
| Analyst / Investor Meet | 4 |
| General | 3 |
| Newspaper Publication | 3 |
| Board Meeting | 2 |
| Trading Window | 2 |
| AGM / EGM | 1 |
| Annual Report | 1 |
| BRSR | 1 |
| Compliance Certificate | 1 |
| Procedural sub-total | 18 |
| Total | 25 |
Disclosure regime
LODR Reg 30
Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.
Filing rhythm · 93 trading days
25 filings · 7 selected · busiest 2026-07-31
Filing rhythm · the twelve most recent
2026-08-242026-10-08
SelectedProcedural
Filings
25 in the window · 5 earlier on record
-
8 October 2026 ·
Crisil ESG Rating
Intimation under Regulation 30 of SEBI LODR, 2015 - Crisil ESG Rating
Company Update / General View filing →
-
7 October 2026 ·
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Reg. 74(5) of SEBI (DP) Regulation, 2018
Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →
-
1 October 2026 ·
Details Of Authorized Persons Under Regulation 30(5) Of The SEBI LODR Regulations, 2015
Details of Authorized Persons under Regulation 30(5) of the SEBI LODR Regulations, 2015
Company Update / General View filing →
-
30 September 2026 ·
Change in Management
Change in Directorate/ Management
Company Update / Change in Management View filing →
-
29 September 2026 ·
Closure of Trading Window
Closure of Trading Window
Insider Trading / SAST / Closure of Trading Window View filing →
-
3 September 2026 ·
-
2 September 2026 ·
Business Responsibility and Sustainability Reporting (BRSR)
Please find attached BRSR for FY 2025-26
Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →
-
2 September 2026 ·
Notice Of 41St Annual General Meeting Of The Company
Please find attached Notice of 41st Annual General Meeting of the Company
AGM/EGM / AGM View filing →
-
2 September 2026 ·
Reg. 34 (1) Annual Report.
Please find attached Annual Report for FY 2025-26
Others / Reg. 34 (1) Annual Report View filing →
-
1 September 2026 ·
-
27 August 2026 ·
Board Meeting Outcome for Approval Of Aarti Drugs Limited Performance Stock Option Plan 2026
approval of Aarti Drugs Limited Performance Stock Option Plan 2026
Board Meeting / Outcome of Board Meeting View filing →
-
24 August 2026 ·
Closure of Trading Window
Closure of Trading Window
Insider Trading / SAST / Closure of Trading Window View filing →
-
24 August 2026 ·
Board Meeting Intimation for 'Aarti Drugs Limited - Performance Stock Option Plan 2026',
Aarti Drugs Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/08/2026 ,inter alia, to consider and approve 'Aarti Drugs Limited - Performance ....
Board Meeting / Board Meeting View filing →
-
14 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation of Analyst/ Institutional Meet
Company Update / Analyst / Investor Meet View filing →
-
10 August 2026 ·
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations")
Disclosure under Regulation 30 of SEBI Listing Regulations
Company Update / General View filing →
-
7 August 2026 ·
Earnings Call Transcript
Q1FY27 Earning call transcript
Company Update / Earnings Call Transcript View filing →
-
4 August 2026 ·
Analyst / Investor Meet - Intimation
Intimation of Analyst /Institutional Investors Meeting
Company Update / Analyst / Investor Meet View filing →
-
3 August 2026 ·
Analyst / Investor Meet - Outcome
Q1FY27 Earning Conference call recording
Company Update / Analyst / Investor Meet View filing →
-
3 August 2026 ·
Newspaper Publication
Newspaper Publication on Financial results
Company Update / Newspaper Publication View filing →
-
31 July 2026 ·
Press Release / Media Release
Aarti Drugs Limited Announces Leadership Transition to Strengthen Governance and Ensure Long-term Strategic Growth
Company Update / Press Release / Media Release View filing →
-
31 July 2026 ·
-
31 July 2026 ·
Board Meeting Outcome for Financial Results For The Quarter Ended June 30, 2026
Financial Results for the quarter ended June 30, 2026
Board Meeting / Outcome of Board Meeting View filing →
-
31 July 2026 ·
Financial Results For The Quarter Ended June 30, 2026
Financial Results for the quarter ended June 30, 2026
Result / Financial Results View filing →
-
29 July 2026 ·
Analyst / Investor Meet - Intimation
Q1 Earning Conference Call
Company Update / Analyst / Investor Meet View filing →
-
24 July 2026 ·
Board Meeting Intimation for Considering The Financial Results For The Quarter Ended June 30, 2026
Aarti Drugs Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve Financial results for the quarter ....
Board Meeting / Board Meeting View filing →
RSS feed for Aarti Drugs Ltd · the 50 most recent filings